I-TRANSFER Improving TRansitions ANd outcomeS oF sEpsis suRvivors
I-TRANSFER 改善脓毒症幸存者的转变和结果
基本信息
- 批准号:10347321
- 负责人:
- 金额:$ 63.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-25 至 2025-11-30
- 项目状态:未结题
- 来源:
- 关键词:Accident and Emergency departmentAcuteAddressAttentionBehavioral ModelCare given by nursesCaregiversCaringCharacteristicsClinicalCodeCommunicationCommunitiesConsolidated Framework for Implementation ResearchDataData SetData SourcesDiagnosisDiscipline of NursingEffectivenessEmergency department visitEquilibriumEvaluationGoalsGuidelinesHealthHealth Care CostsHealth PersonnelHealth ProfessionalHealth ServicesHealthcare IndustryHeart failureHomeHome Care ServicesHome Health AgencyHospitalizationHospitalsHybridsIndustryInpatientsInterventionKnowledgeLength of StayMedicalMedicareMedicare claimMedication ManagementMedicineModelingMonitorMorbidity - disease rateMyocardial InfarctionNursesOutcomeOutpatientsPatientsPersonsPneumoniaPopulationProcessProfessional OrganizationsProtocols documentationProviderPublishingQualitative MethodsRandomizedRecoveryRegistered nurseResearch PersonnelSamplingScienceSepsisSiteSurvivorsTalentsTestingTimeUnited StatesVisitVisiting NurseVulnerable PopulationsWorkacute carebaseclinical research sitecohortcomparative effectiveness studycomparison interventioncostdesigneffectiveness testingexperiencefollow-uphealth care servicehospital readmissionimplementation barriersimplementation determinantsimplementation scienceimprovedimproved outcomeinnovationinsightmortalitypreventrandomized trialreadmission ratestreatment as usual
项目摘要
Acute care hospitals discharge over 1.5 million sepsis survivors annually. Sepsis survivors are twice as likely
as non-sepsis patients to be readmitted within 30 days, with 32% of those readmissions occurring within 7
days. Annually, over one third of sepsis survivors transition to skilled home health care (HHC) after their
hospitalization where nurses monitor for reinfection, support uninterrupted medication management, and work
with patients, caregivers, other providers to support continued recovery. This proposed competing renewal is
based on HHC best practice evidence generated by our previous study (RO1-NR016014) showing the value of
early visits by registered nurses and early outpatient provider follow-up. We found that 30-day rehospitalization
rates were 7 percentage points lower (a 41% relative reduction) when sepsis survivors received a HHC nursing
visit within 2 days of hospital discharge, at least 1 more visit the first week, and an outpatient provider follow-up
visit by 7 days compared to those without timely follow-up. However, nationwide, only 28% of sepsis survivors
who transitioned to HHC received this early visit protocol because several barriers to achieving this protocol
exist. To advance the science, the proposed study will test the effectiveness of this practice in the real
world and study the implementation with a pragmatic, Type 1 hybrid, stepped wedge randomized trial
in partnership with dyads of acute and HHC stakeholders. Aim 1: Test the effectiveness of the I-
TRANSFER intervention compared to usual care on 30-day rehospitalization and emergency department use
among sepsis survivors receiving home health care. The stepped wedge protocol will involve a baseline period
with no intervention, and two steps where randomized dyads provide the intervention. In addition to the usual
care/control periods from the dyad sites, additional survivors from national data will provide a much larger
sample of control observations, weighted to produce covariate balance. The hypotheses will be tested using
generalized mixed models with covariates guided by the Anderson Behavioral Model of Health Services. In aim
2 we will: Produce insights and generalizable knowledge regarding the context, processes, strategies, and
determinants of I-TRANSFER implementation. The implementation aim is guided by the Consolidated
Framework for Implementation Research. As the largest HHC study of its kind and the first to transform this
type of care through implementation science, the proposed study has the potential to produce new knowledge
about the process of transition to and care in home health. If effective, the impact of this intervention during this
common transition process could be widespread, improving the outcomes for a growing, vulnerable population
of sepsis survivors. An Advisory Group of national experts will assist with widespread dissemination of the
study results.
急诊医院每年让150多万败血症幸存者出院。败血症幸存者的可能性是前者的两倍
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kathryn Helene Bowles其他文献
Kathryn Helene Bowles的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kathryn Helene Bowles', 18)}}的其他基金
I-TRANSFER Improving TRansitions ANd outcomeS oF sEpsis suRvivors
I-TRANSFER 改善脓毒症幸存者的转变和结果
- 批准号:
10824878 - 财政年份:2023
- 资助金额:
$ 63.67万 - 项目类别:
I-TRANSFER Improving TRansitions ANd outcomeS oF sEpsis suRvivors
I-TRANSFER 改善脓毒症幸存者的转变和结果
- 批准号:
10527374 - 财政年份:2015
- 资助金额:
$ 63.67万 - 项目类别:
Sepsis Survivors' Post-Acute Outcomes: Impact of Early Home Health and MD Visits
败血症幸存者的急性后结果:早期家庭健康和医学博士就诊的影响
- 批准号:
9007054 - 财政年份:2015
- 资助金额:
$ 63.67万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 63.67万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 63.67万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 63.67万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 63.67万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 63.67万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 63.67万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 63.67万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 63.67万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 63.67万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 63.67万 - 项目类别:
Operating Grants